EDITORIAL
Main Article Content
Keywords
Ontario Drug Benefit Formulary
Abstract
Invited Editorial
References
1. Rawson N, Chhabra A. Public reimbursement of prescription drugs used for off-label indications in Ontario. J Pop Ther Clin Pharmacol 2018;25(2).
2. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age?related macular degeneration. Cochrane Database System Rev 2014;9: CD011230.
3. Eguale T, Buckeridge D, Verma A, et al. Association of off-label dur use and adverse drug events in an adult population. JAMA Int Med 2016;176:55–63.
4. CADTH. Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions - recommendations report. Ottawa; 2016. Available at: https://www.cadth.ca/anti-vascular-endothelial-growth-factor-drugs-retinal-conditions
5. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Data Syst Rev 2017;2: MR000033.
2. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age?related macular degeneration. Cochrane Database System Rev 2014;9: CD011230.
3. Eguale T, Buckeridge D, Verma A, et al. Association of off-label dur use and adverse drug events in an adult population. JAMA Int Med 2016;176:55–63.
4. CADTH. Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions - recommendations report. Ottawa; 2016. Available at: https://www.cadth.ca/anti-vascular-endothelial-growth-factor-drugs-retinal-conditions
5. Lundh A, Lexchin J, Mintzes B, Schroll JB, Bero L. Industry sponsorship and research outcome. Cochrane Data Syst Rev 2017;2: MR000033.
Article Sidebar
Published
Sep 24, 2018
Article Details
How to Cite
Lexchin, J. (2018). EDITORIAL. Journal of Population Therapeutics and Clinical Pharmacology, 25(2), e31-e32. https://doi.org/10.22374/1710-6222.25.2.4
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.